Skip to content

Moderna

US · MRNA #406 by market cap Listed 2018
195.00 -4.33 -2.17%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 199.29 -0.02%
After-hours 199.30 +2.21%
Overnight 197.88 -0.73%
269.0045.64195.002026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on MRNA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +409.2% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has fallen to 8.3% of float.
  • Analyst tilt is Hold.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days A → A

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 54.8% Better than 69%
Operating margin -159.9% Better than 6%
Net margin -146.8% Better than 6%
Return on equity -28.9% Better than 13%
Return on invested capital -28.2% Better than 11%
Momentum A+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 34.4% Better than 99%
6-month return 316.0% Better than 100%
12-month return (ex latest month) 754.3% Better than 100%
Distance below 52-week high 30.6% Better than 42%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 3.3x Better than 76%
Debt to assets 10.6% Better than 69%
Interest coverage -275.8x Better than 3%
Free cash flow / net income 54.8% Better than 15%
Analyst View F

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 15.4% Better than 7%
Upside to average target -24.8% Better than 0%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -12.70%
1M -19.45%
3M +46.26%
6M +305.24%
YTD +561.24%
1Y +772.09%
3Y +146.96%
5Y -26.07%

Key statistics

Price & volume

Prev close
199.33
Open
200.07
Day range
191.46 - 210.00
Avg price
199.48
Volume
9.69M
Turnover
1.93B
Amplitude
9.30%
52-week range
23.55 - 280.80

Valuation

P/E
-26.86
P/E (TTM)
-27.70
P/B
11.54
EPS
-7.26
Net profit
-2.94B
Net assets
6.84B

Share structure

Market cap
78.90B
Float cap
72.59B
Shares out
404.62M
Float shares
372.26M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2018-12-07
52-week range 67% of range
23.55 280.80

30.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+404.17M net over the window

Short interest

Shares short
33.19M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Moderna (MRNA)?

Moderna last traded at 195.00. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Moderna's market cap?

About 78.90B.

What is the P/E ratio of Moderna?

The trailing twelve-month P/E is -27.70. The Valuation tab shows it against the stock's own five-year range.

Does Moderna pay a dividend?

Moderna does not currently pay a regular dividend.

Is Moderna a buy according to analysts?

The consensus of 13 analysts is a Hold rating, with an average 12-month price target of 146.67, which implies 24.8% downside from the current price. This is not investment advice.

What is Moderna's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Moderna a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Moderna discussion 0 comments

Add a comment